Teladoc Health (TDOC) News Today

Teladoc Health, Inc. (NYSE: TDOC) shares have declined sharply after the company’s second-quarter results and reduced 2026 outlook raised concerns about weakening demand, particularly in its BetterHelp mental-health business. Trading volume was also above average, indicating heightened investor activity.

• Positive Sentiment: Teladoc reported a second-quarter adjusted loss of $0.21 per share, better than the consensus estimate of a $0.24 loss. Strength in Integrated Care and international operations helped offset weakness in BetterHelp. Teladoc Health Q2 Earnings Beat Estimates on Integrated Care Strength
• Positive Sentiment: Management’s cost controls and efficiency measures appear to be narrowing losses over the first half of 2026, while some investors see the stock as potentially undervalued following the selloff. Teladoc Health Could Be Undervalued
• Neutral Sentiment: Canaccord Genuity maintained a Buy rating but lowered its price target from $11 to $10. Separately, traders purchased about 15,650 call options, roughly 30% above typical volume, suggesting some speculative bullish positioning but not necessarily a change in fundamentals.
• Negative Sentiment: Second-quarter revenue fell 4% year over year to $606.9 million, missing analysts’ $615.4 million estimate. Teladoc also posted a $38.9 million net loss, or $0.21 per share, compared with a $0.19 loss in the year-earlier quarter. Teladoc Tumbles on Revenue Forecast Cut
• Negative Sentiment: The key pressure is BetterHelp, where shifting demand reduced cash-pay revenue. After a 12% annual decline in the latest quarter, the company indicated the division could decline as much as 19% for the full year, undermining expectations for a recovery. Teladoc Health Investigation Notice
• Negative Sentiment: Teladoc’s third-quarter revenue outlook of approximately $589 million was below expectations, and the company lowered its full-year revenue forecast. The weaker outlook outweighed the adjusted earnings beat and caused analysts and investors to reset expectations for growth and profitability. Teladoc Stock Plummets on Revenue Miss and Lowered Outlook
• Negative Sentiment: Levi & Korsinsky announced a pending investigation into Teladoc, adding potential legal and reputational risk to an already weak earnings narrative. The investigation notice does not establish wrongdoing, but it may further weigh on sentiment.